Zydus Lifesciences Q4 Results: Revenue Surges 18%, Profit Down

Zydus Lifesciences Ltd.'s consolidated net profit fell 1% in the quarter ended March due to exceptional items, according to an exchange filing on Tuesday.

The company reported impairment charges of Rs 220 crore during the quarter from its Brazil business and its unit Zydus Worldwide DMCC.

The bottom line came in at Rs 1,171 crore in the January-March period as compared to Rs 1,182 crore in the same period last year.

The pharmaceutical firm approved a final dividend of Rs 11 per share at a face value of Re 1 each, subject to the approval from the required stakeholders at the annual general meeting.

The record date has been set as July 25, 2025, to determine the shareholders eligible for the final dividend for the financial year ended March 31, 2025.

Zydus Lifesciences Q4 Highlight (Consolidated, YoY)

• Revenue up 18% to Rs 6,527.9 crore versus Rs 5,533.8 crore.

• Net profit down 1% to Rs 1,170.9 crore versus Rs 1,182.3 crore.

• Ebitda up 30% to Rs 2,125.5 crore versus Rs 1,630.5 crore.

• Margin at 32.6% versus 29.5%.

During the quarter, the company had an exceptional item of Rs 220 crore due to impairment of Goodwill related to Brazil business and of a product-related intangible held by a wholly owned subsidiary.

Zydus Lifesciences' branded business recorded a 11% year-on-year growth, citing a high uptick in pillar brands and innovation products, according to the investor presentation.

The company's secondary sales rose 10% year-on-year, exceeding market growth. This was driven by strong results in the chronic segment and higher-than-market expansion in key therapies, the presentation stated.

Its chronic portfolio has grown consistently in the last three years, reaching 43%.

The personal care segment witnessed strong consumer demand, leading to robust double-digit growth. Similarly, the food and nutrition segment posted double-digit growth, driven by category expansion, product innovation, and the acquisition of Naturell (India) Pvt., it said.

Shares of Zydus Lifesciences fell as much as 2.68% to Rs 887.15 apiece. The stock pared losses to trade 2.17% lower at Rs 891.50 apiece, as of 1:48 p.m. This compares to a 0.66 decline in the NSE Nifty 50 Index.

Share price has fallen 8.27% on a year-to-date basis and is down 18.08% in the last 12 months. The relative strength index was at 51.22.

Out of 33 analysts tracking the company, 17 maintain a 'buy' rating, 10 recommend a 'hold,' and six suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 19.5%.